ReviewCancer reports (Hoboken, N.J.)2023

Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.

Jaume Mora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.